Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Virbac in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $435.44.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Virbac.
Virbac SA engages in the manufacture and sale of veterinary medicines. The firm develops vaccines, antibiotics, anesthetics, dermatological products, and drugs for pest control, inflammation, dental care, and ophthalmological conditions of pets and livestock. It also offers food and electronic identification chips. The company was founded by Pierre-Richard Dick and Max Rombi in 1968 and is headquartered in Carros, France.